König, Christina
Martens-Lobenhoffer, Jens
Czorlich, Patrick
Westphal, Manfred
Bode-Böger, Stefanie M.
Kluge, Stefan
Grensemann, Jörn
Funding for this research was provided by:
Infectopharm
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 4 July 2022
Accepted: 12 March 2023
First Online: 24 April 2023
Declarations
:
: This analysis was reported to the Ethics Committee of the Hamburg Chamber of Physicians (Reference: WF-028/20, February 11, 2020). Due to the non-interventional nature of this study and anonymous recording of data, written informed consent was waived.
: Not applicable.
: CK received a research grant from the DAMP foundation and lecture fees from Shionogi. JML has no conflicts of interest. MW has no conflicts of interest. PC has no conflicts of interest. SK received research support from Ambu, Daiichi Sankyo, ETView Ltd, Fisher & Paykel, Pfizer, and Xenios, lecture fees from Astra, C.R. Bard, Baxter, Biotest, Cytosorbents, Daiichi Sankyo, Fresenius, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer, Philips, and Zoll, and consultant fees from Bayer, Fresenius, Gilead, MSD and Pfizer. SMBB has no conflicts of interest. JG has received research support from Adroit Surgical, Ambu, ETView, Infectopharm, and Pfizer, and received consultant and lecture fees from Drägerwerk, Fresenius Medical, GE Healthcare, and Smith Medical, and holds shares from AstraZeneca, Bayer, Gilead, and Pfizer.